Cost Effectiveness Analysis Analgetics Diabetic Neuropathy Patients At Puskesmas Kaliwungu Kudus And RSI Sultan Agung Semarang
Abstract
Diabetic neuropathy that affects peripheral nervous system as a complication of Diabetes Mellitus (DM). A total of 1785 DM patients in Indonesia, 63.5% experienced neuropathy. Choosing the right analgetics for diabetic neuropathy patients will improve therapy, so the costs of using the drugs will also be affordable. This study aims to cost effectiveness analysis of analgetics in diabetic neuropathy patients at Kaliwungu Kudus Health Center and Sultan Agung Islamic Hospital in Semarang. This study was hold in September - November 2020.
The research method was cohort retrospective and collected data with purposive sampling involving all populations who had complete medical record and include inclusion criteria. The instruments used were data report, medical record and details of the patient's payment. The cost data used was based on a payer perspective from direct medical costs related to drug prices based on perspective of the hospital and e-catalogue or BPJS. Then CEA to determine which therapy was more cost-effective therapy from the use of analgeticss by calculating the ACER (Average Cost Effectiveness Ratio) and ICER (Incremental Cost Effectiveness Ratio).
The results show that the cost effectiveness of analgetics at the Kaliwungu Kudus Health Center is diclofenac sodium 50 mg and a combination of 500 mg paracetamol and 200 mg ibuprofen with ICER values of Rp. 2765.02 and Rp.-8,837.94. Meanwhile, at the Sultan Agung Islamic Hospital in Semarang, are single amitriptyline and a combination of amitriptyline and tramadol, with the ICER value on single amitriptyline which is Rp. -7,690.08.
References
2. Osvaldo José Moreira do Nascimento, Camila Castelo Branco Pupe EBUC. Diabetic neuropathy. 2016;17(Suppl 1):46–51.
3. Kemenkes RI. Pusat Data dan Informasi Situasi dan Analisis Diabetes. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014.
4. Dinkes Jateng. Buku Profil Kesehatan Provinsi Jawa Tengah Tahun 2013. Semarang: Dinkes Jateng; 2013.
5. Pop-busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy : A Position Statement by the American Diabetes Association. 2017;40(January):136–54.
6. Lozeron P, Kubis N. Management of neuropathic pain. Rev Med Interne. 2015;36(7):480–6.
7. National Institute for Health Care and Exellence. Neuropathic pain in adults : pharmacological management in non- specialist settings. NICE Guidel. 2013;(November 2013):1–36.
8. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol [Internet]. 2015;14(2):162–73. Tersedia pada: http://www.ncbi.nlm.nih.gov/pubmed/25575710%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4493167
9. Majdinasab N, Kaveyani H, Azizi M. A comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy. Drug Des Devel Ther. 2019;13:1985–92.
10. Ms Z, Carolia N. Efektivitas Acetaminophen dan Antidepresan dalam Tatalaksana Nyeri Effectivity of Acetaminophen and Antidepressants in Pain Management. 2019;8:221–6.
11. BPJS Kesehatan. Peraturan Baddan Penyelenggara Jaminan Sosisal Kesehatan Nomor 2 Tahun 2015 Tentang Norma Penetapan Besaran Kapitasi dan Pembayaran Kapitasi Berbasis Pemenuhan Komitmen Pelayanan pada Fasilitas Kesehatan Tingkat Pertama. Jakarta: Badan Penyelenggara Jaminan Sosial Kesehatan; 2015. 3 hal.
12. Qiyaam N, Abdul R, Pia DM, Lestiono. Analisis Efektivitas Biaya ( Cost Effectiveness Analysis ) Penggunaan Amitryptiline Dibandingkan Carbamazepine pada Pasien Nyeri Neuropatik ( Studi Kasus Di Klinik Saraf Rumkital . 2015;2(2):47–55.
13. Andayani T.M. Farmakoekonomi Prinsip dan Metodologi. Yogyakarta: Bursa Ilmu; 2013.
14. DiPiro J.T., Talbert R.L., Yee G.C., Matzke G.R. WBG and PLM. Pharmacotherapy: A Pathophysiologic Approach, 8th ed. United State of America: Mc Graw - Hill; 2011.
15. Citraningtyas G, Ruru RI, Nalang A, Ratulangi US. Analisis Efektifitas Biaya Penggunaan Antibiotik Sefiksim dan Sefotaksim Pasien Diare di Rumah Sakit X Tahun 2017. 2019;8(4):145–52.
16. Kementrian Kesehatan Republik Indonesia. Pedoman Penerapan Kajian Farmakoekonomi. Jakarta: Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan Jakarta; 2013.
17. Rima Novia Putri AW. Gambaran karakteristik penderita neuropati perifer diabetik. J Keperawatan Abdurrab. 2017;4–9.
18. Halawa MR, Karawagh A, Zeidan A, Mahmoud AEDH, Sakr M, Hegazy A. Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Curr Med Res Opin. 2010;26(2):337–43.
19. Prasetyo MA. Pengaruh Penambahan Alpha Lipoic Acid Terhadap Perbaikan Penderita Polineuropati Diabetika [Tesis]. Universitas Diponegoro Semarang; 2011.
20. Amour, A. A., Chamba, N., Kayandabila J, Lyaruu, I. A., Marieke, D., Shao, E. R. &, Howlett W. Prevalence, patterns, and factors associated with peripheral neuropathies among diabetic patients at tertiary hospital in the kilimanjaro region: descriptive cross-sectional study from north-eastern tanzania. Int J Endocrinol. 2019;5404781.
21. Abdelsadek, S. E., El Saghier, E. O. A, Raheem SI. Serum 25(OH) vitamin D level and its relation to diabetic peripheral neuropathy in Egyptian patients with type 2 diabetes mellitus. Egypt J Neurol psychiatry Neurosurg. 2018;54(1), 36.
22. Menkes RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 21 Tahun 2016 tentang Penggunaan Dana Kapitasi Jaminan Kesehatan Nasional untuk Jasa Pelayanan Kesehatan dan Dukungan Biaya Operasional pada Fasilitas Kesehatan Tingkat Pertama Milik Pemerintah Daerah. Jakarta: Menteri Kesehatan Republik Indonesia; 2016.
